![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. 10381-75-6
2. Bromotheophylline
3. 8-bromo-1,3-dimethyl-1h-purine-2,6(3h,9h)-dione
4. Theophylline, 8-bromo-
5. 8-bromo-1,3-dimethyl-7h-purine-2,6-dione
6. 1h-purine-2,6-dione, 8-bromo-3,7-dihydro-1,3-dimethyl-
7. C7h7brn4o2
8. 8-bromotheophyline
9. 8-bromo-1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dione
10. 8-bromo-1,3-dimethyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione
11. Unii-fzg87k1mq6
12. Fzg87k1mq6
13. 8-bromo-1,3-dimethyl-1h-purine-2,6(3h,7h)-dione
14. Predema
15. 8-bromo-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
16. Chembl316160
17. Dtxsid7044768
18. Einecs 233-846-6
19. Mfcd00022664
20. Nsc 164940
21. Nsc-164940
22. Ncgc00167564-01
23. 1h-purine-2,6-dione, 8-bromo-3,9-dihydro-1,3-dimethyl-
24. Dtxcid5024768
25. Cas-10381-75-6
26. 8-bromo-theophylline
27. 8-bromo-1,3-dimethyl-3,7-dihydro-1h-pyrine-2,6-dione
28. Oprea1_299436
29. Oprea1_509676
30. Mls004754491
31. Schembl237881
32. C7-h7-br-n4-o2
33. Tox21_112559
34. Bbl012666
35. Bdbm50045345
36. Ccg-19376
37. Mfcd01848460
38. Nsc164940
39. Stk803299
40. 8-bromotheophylline [usp-rs]
41. Akos000274376
42. Akos001283003
43. Tox21_112559_1
44. Am85456
45. Db14018
46. Gs-5727
47. Hy-w088152
48. Ncgc00167564-03
49. Ncgc00167564-04
50. Smr002397689
51. Sy023545
52. B3456
53. Cs-0130336
54. Ft-0636693
55. En300-17892
56. 8-bromanyl-1,3-dimethyl-7h-purine-2,6-dione
57. H10528
58. Ab01300038-01
59. Ab01300038_03
60. A800812
61. Af-399/37411012
62. Sr-01000479300
63. 1h-purine-2, 8-bromo-3,7-dihydro-1,3-dimethyl-
64. Sr-01000479300-1
65. W-108837
66. Q27278353
67. Z57161790
68. 8-bromo-1,3-dimethyl-1h-purine-2,6(3h, 7h)-dione
69. F0807-0406
Molecular Weight | 259.06 g/mol |
---|---|
Molecular Formula | C7H7BrN4O2 |
XLogP3 | 1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 0 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 69.3 |
Heavy Atom Count | 14 |
Formal Charge | 0 |
Complexity | 297 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Bromotheophylline is used as a diuretic and also, in combination with [DB00316], it is used for the relief of temporary water weight gain, bloating, swelling and full feeling associated with the premenstrual and menstrual periods.
Absorption
When administered after one single oral dosage, bromotheophylline is rapidly absorbed and it reaches a maximal plasma concentration of 2.5 mg/L in 0.78 hours. The mean residence time is registered to be of 12 hours with an AUC in the first 8 hours of 27 mg.h/L.
Route of Elimination
This pharmacokinetic property has not been determined.
Volume of Distribution
This pharmacokinetic property has not been determined.
Clearance
This pharmacokinetic property has not been determined.
This pharmacokinetic property has not been determined.
The apparent elimination half-life is registered to be 21.35 hours.
Bromotheophylline is part of the group of the xanthines. As part of this group, it is thought that bromotheophylline increases the permeability of the renal tubule, increases glomerular filtration rate and inhibits the sodium reabsorption in the proximal tubule. It is thought but not confirmed that pamabrom as a mixture seems to have an additional mechanism of action in which the presence of 2-amino-2-methyl-1-propanol produces the suppression of the antidiuretic hormone in the posterior pituitary gland.